Short-term knemometry and urine cortisol excretion in children treated with fluticasone propionate and budesonide: a dose response study.
Few thorough comparisons of the systemic effects of inhaled corticosteroids in children are available. The aim of this study was to compare the effect of budesonide and fluticasone propionate on short-term lower leg growth. Fluticasone propionate, budesonide and placebo were administered for 2 weeks in a randomized, double-blind, double-dummy, cross-over design. Twenty four children aged 6-12 yrs received 200 microg x day(-1) of each drug, or placebo. Another 24 children aged 6-12 years received 400 microg x day(-1) of each drug, or placebo. Dry powder inhalers were used. Lower leg length was measured by knemometry twice a week during all three treatment periods, and 24 h cortisol excretion in the urine was measured at the end of each period. In the low-dose group, lower leg growth rate was the same during treatment with placebo (0.35 mm x week(-1)), fluticasone propionate (0.38 mm x week(-1)) or budesonide (0.26 mm x week(-1)). No significant difference (p=0.39) in lower leg growth rate was found between treatment with 400 microg x day(-1) budesonide (0.30 mm x week(-1)) and 400 microg fluticasone propionate treatment (0.37 mm x week(-1)). Growth rate during treatment with budesonide, 400 microg x day(-1), was significantly lower than during placebo treatment (0.52 mm x week(-1)). Cortisol excretion in the urine during treatment with 200 microg x day(-1) fluticasone propionate was significantly reduced as compared with placebo (p=0.006), but not when compared with 200 microg x day(-1) budesonide (p=0.07). Budesonide 200 microg x day(-1) was not significantly different from placebo. Fluticasone propionate and budesonide, both at 400 microg x day(-1), resulted in a significant reduction in cortisol excretion in the urine as compared with placebo (p=0.001). It is concluded that, dose-for-dose, budesonide Turbuhaler and fluticasone propionate Diskhaler have similar systemic effects.
Agertoft
L
L
Dept of Paediatrics, Kolding Hospital, Denmark.
Pedersen
S
S
D000280:Administration, Inhalation; D000287:Administration, Topical; D000336:Aerosols; D000730:Androstadienes / Q000008:administration & dosage* / Q000494:pharmacology; D000886:Anthropometry; D000893:Anti-Inflammatory Agents / Q000008:administration & dosage* / Q000494:pharmacology; D001249:Asthma / Q000188:drug therapy*; D019819:Budesonide; D002648:Child; D018592:Cross-Over Studies; D004305:Dose-Response Relationship, Drug; D004311:Double-Blind Method; D005260:Female; D000068298:Fluticasone; D006128:Growth / Q000187:drug effects; D006801:Humans; D006854:Hydrocortisone / Q000652:urine*; D007866:Leg / Q000254:growth & development; D008297:Male; D011282:Pregnenediones / Q000008:administration & dosage* / Q000494:pharmacology
D000336:Aerosols; D000730:Androstadienes; D000893:Anti-Inflammatory Agents; D011282:Pregnenediones; D019819:Budesonide; D000068298:Fluticasone; D006854:Hydrocortisone